Management of Tirzepatide Therapy

Introduction to Tirzepatide

Tirzepatide significantly delays gastric emptying, affecting the absorption of oral medications and requiring monitoring for medications with narrow therapeutic indices, as recommended by the American Diabetes Association 1, 2

Tirzepatide may reduce the effectiveness of oral contraceptives due to its effect on gastric emptying, and patients on oral hormonal contraceptives should consider adding a non-oral contraception method 1, 3
The American Diabetes Association recommends monitoring for medications with narrow therapeutic indices when using tirzepatide, and closer INR monitoring for patients on warfarin 1, 3
Tirzepatide has relatively few clinically significant drug interactions, with the primary interaction mechanism being delayed gastric emptying, which may affect absorption of oral medications 3

There is insufficient evidence to recommend taking Pendulum supplements while on tirzepatide due to potential interactions affecting medication absorption, and patients should consult their healthcare provider before combining these products 1
Patients should consider timing separation if both tirzepatide and Pendulum supplements are used, taking supplements at a consistent time relative to tirzepatide injection to establish a pattern that can be monitored for effectiveness 1

Tirzepatide is administered as a once-weekly subcutaneous injection, with a maximum approved dose of 15 mg weekly, as recommended by the FDA 2
Patients should begin with the lowest approved dose and gradually increase the dose at 4-week intervals as tolerated, assessing efficacy and side effects before each dose increase, as recommended by the American Diabetes Association 2

Tirzepatide is indicated as an adjunctive treatment to diet and exercise for improving glycemic control in adults with type 2 diabetes, particularly beneficial for patients with obesity, metabolic associated steatohepatitis (MASH), or non-alcoholic steatohepatitis (NASH) confirmed by biopsy 2, 4, 5
Tirzepatide is recommended for patients with type 2 diabetes and overweight/obesity, as it prioritizes weight reduction and glycemic control, and is positioned as a preferred agent by the American Diabetes Association due to its beneficial effect on weight 5
For patients with poorly controlled diabetes (A1C >8%), tirzepatide is recommended for superior glycemic control and weight reduction 6

Tirzepatide may be used in combination with SGLT2 inhibitors due to complementary mechanisms of action, and may be considered for patients with established cardiovascular disease if greater glucose and weight reduction are priorities 2
Tirzepatide can be considered in combination with pioglitazone for the treatment of hyperglycemia in adults with MASH confirmed by biopsy 2

Tirzepatide has an emerging evidence suggesting favorable cardiovascular safety profile, with a definitive cardiovascular outcomes trial (SURPASS-CVOT) currently ongoing 6
The cardiovascular safety profile of tirzepatide appears favorable based on current evidence, with no concerning signals identified in systematic reviews and network meta-analyses regarding its effect on major adverse cardiovascular events (MACE) 7
Tirzepatide is a dual agonist that acts on both Glucagon-like peptide-1 (GLP-1) receptors and Glucose-dependent insulinotropic polypeptide (GIP) receptors, and has demonstrated cardioprotective effects through several mechanisms, including improved myocardial substrate utilization, anti-inflammatory effects, anti-atherosclerotic effects, reduced myocardial ischemia injury, lower systemic and pulmonary vascular resistance, and improved lipid profiles 8

Patients should monitor for changes in tirzepatide effectiveness or digestive symptoms when adding supplements, and report any new digestive symptoms to their healthcare provider 1
Both tirzepatide and dulaglutide have a similar safety profile, with gastrointestinal effects (nausea, vomiting, diarrhea) and risk of hypoglycemia (low when used as monotherapy) 9